NCT03348046View on ClinicalTrials.gov

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

CompletedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

March 23, 2017

Primary Completion Date

April 14, 2019

Study Completion Date

April 14, 2019

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Biosimilar Infliximab

A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

Trial Locations (2)

Unknown

Prince Hamza Hospital, Amman

Jordan University of Science and Technology- King Abdallah University Hospital, Irbid

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Hikma Pharmaceuticals LLC

INDUSTRY

NCT03348046 - Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan | Biotech Hunter | Biotech Hunter